Ipriflavone (Osteofix)
(Synonyms: 依普黄酮) 目录号 : GC13331
An Analytical Reference Standard
Cas No.:35212-22-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Ipriflavone is a synthetic isoflavone derivative used to suppress bone resorption.
Ipriflavone inhibits the proliferation and DNA synthesis of MDA-231 cells and blocks the ligand-induced phosphorylation of Tyr(845) of the EGFR. Ipriflavone does not promote apoptosis of MDA-231 cells[1]. Ipriflavone also promotes the deposition of calcium and the formation of mineralized nodules by newborn rat calvarial osteoblast-like cells as well as the activity of alkaline phosphatase[2].
Daily oral administration of ipriflavone at 12 mg/mouse significantly inhibits the development of new osteolytic bone metastases and the progression of established osteolytic lesions, prolonging the life of tumor-bearing mice. Ipriflavone reduces the number of osteoclasts at the bone-cancer interface with no severe adverse effects on the host[1]. 1-month treatment with ipriflavone increases bone density and improves the biomechanical properties of adult rat male bones without altering mineral composition[3]
Reference：
[1]. Iisaki T, et al. Ipriflavone inhibits osteolytic bone metastasis of human breast cancer cells in a nude mouse model. Int J Cancer. 2002 Aug 1;100(4):381-7.
[2]. Hagiwara H, et al. Ipriflavone down-regulates endothelin receptor levels during differentiation of rat calvarial osteoblast-like cells. J Biochem. 1999 Jul;126(1):168-73.
[3]. Civitelli R, et al. Ipriflavone improves bone density and biomechanical properties of adult male rat bones. Calcif Tissue Int. 1995 Mar;56(3):215-9.
Cell experiment: | Ipriflavone is dissolved in absolute ethanol and added to the medium at 1-50 μM. The final ethanol concentrations are <0.5% (v/v). MDA-231 cells are seeded in 35 mm culture dishes in DMEM supplemented with 10% FBS in the presence of ipriflavone (1, 10 or 50 μM) or ethanol. After 48 hr incubation, the medium is changed with fresh medium containing the same concentrations of ipriflavone or ethanol. After incubation for 24, 48, 72 and 96 hr from the initial seeding, cells are treated with trypan blue to estimate the number of viable cells[1]. |
Animal experiment: | Rats: To assess the potential impact of ipriflavone on the biomechanical properties and mineral composition of bone, adult male rats are orally administered two doses (200 or 400 mg/kg bw) of ipriflavone for 1 month. Bone biomechanics are evaluated by vibration damping, an index of strain energy loss, and impact strength[3]. Mice: Ipriflavone is suspended in water containing 0.5% (w/v) methylcellulose and given to mice orally at 6 or 12 mg/0.2 mL daily, which is equivalent to 200 or 400 mg/kg body weight. MDA-231 cells are injected s.c. into the interscapular space of nude mice (on day 0), which are then given ipriflavone (6 or 12 mg/mouse) or the methylcellulose solution orally from day 1 to day 27. Tumor growth is analyzed twice a week by measuring the tumor volume[1]. |
References: [1]. Iisaki T, et al. Ipriflavone inhibits osteolytic bone metastasis of human breast cancer cells in a nude mouse model. Int J Cancer. 2002 Aug 1;100(4):381-7. | |
| Cas No. | 35212-22-7 | SDF | |
| 别名 | 依普黄酮 | ||
| Canonical SMILES | O=C1C(C(OC=C1C2=CC=CC=C2)=C3)=CC=C3OC(C)C | ||
| 分子式 | C18H16O3 | 分子量 | 280.32 |
| 溶解度 | DMF: 20 mg/mL,DMF:PBS (pH 7.2) (1:4): 0.2 mg/mL,DMSO: 10 mg/mL,Ethanol: 1 mg/mL | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.5674 mL | 17.8368 mL | 35.6735 mL |
| 5 mM | 0.7135 mL | 3.5674 mL | 7.1347 mL |
| 10 mM | 0.3567 mL | 1.7837 mL | 3.5674 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet